To hear about similar clinical trials, please enter your email below
Trial Title:
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
NCT ID:
NCT05565118
Condition:
High Grade Glioma
Glioblastoma
Conditions: Official terms:
Glioblastoma
Glioma
Conditions: Keywords:
High Grade Glioma
Glioblastoma
Neural Recording
Electrical Activity
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Intervention model description:
Participants undergoing surgical resection will have a regional recording of neuronal
electrical activity that will be measured in a minimum of 4 peritumoral anatomic zones
via depth electrodes, overlying the cortex of the lesion via a subdural grid, within the
presumed tumor, and in adjacent presumed normal brain. Recording findings specific to
these anatomo-electro-clinical zones will be correlated with the presence/degree of
contrast-enhancing tumor on MRI at recurrence. Additionally, biopsies will be obtained in
these depth electrode regions for correlative studies.
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
Standard Surgical Treatment
Description:
During this surgery, participants will also undergo a tissue biopsy at recording sites
for correlation to neural recording data.
Arm group label:
Standard Surgical Treatment + Intraoperative Electrocorticography
Intervention type:
Procedure
Intervention name:
Intraoperative Electrocorticography
Description:
Each participant will undergo intraoperative electrocorticography (ECOG) through subdural
grid (SDG) and depth electrode (DE) via FDA-cleared, standardized, brain recording
technology.
Arm group label:
Standard Surgical Treatment + Intraoperative Electrocorticography
Summary:
The purpose of this study is to test the safety and feasibility of recording brain
activity within and around high-grade glioma tumors at the time of surgery. A small
biopsy will be taken at the sites of the recordings.
Detailed description:
High-grade gliomas are incurable primary brain tumors. Recent data support that glioma
cells can integrate within neuronal circuits. Glioma cells and neurons communicate via
electrical impulses and chemically, through neurotransmitters. This crosstalk has been
shown to promote glioma cell migration and invasion in preclinical models. However, the
nature of the electrical activity and underlying molecular mechanisms are poorly
understood. The long-term goal of this study is to determine the impact of high
electrical activity and pattern of activity on tumor invasion, and mechanistic basis of
its regulation and functional consequences. This phase I safety and feasibility study is
being proposed as a first step toward dissecting the connection between electrical
activity and glioma behavior. The goal is to determine the safety and feasibility of
recording electrical activity in the tumor-neuron interface using technologies that are
already being used clinically for participants undergoing brain surgery.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Participants who have the appearance of high-grade glioma (HGG, WHO Grade 3 and 4,
including GBM) on MR imaging are allowed to consent and will undergo the procedure
if the frozen is consistent with HGG
OR
- Participants with a history of histologically-confirmed diagnosis of high- grade
glioma that are undergoing resection of a recurrent/progressive tumor that is likely
recurrent/progressive high- grade glioma as identified on preoperative MR imaging
- Age ≥ 18 years old
- Volumetric MRI within 1 month prior to surgery
- Karnofsky performance status of 60 or higher
- The participant (or legally acceptable representative if applicable) provides
written informed consent for the trial.
- Participants must be considered appropriate neurosurgical candidates with the
following screening/baseline laboratory values within 1 month prior to surgery:
- Absolute neutrophil count ≥ 1500/µL
- Platelets ≥ 100 000/µL
- International normalized ratio (INR) OR prothrombin time (PT) Activated partial
thromboplastin time (aPTT) ≤1.5 × Upper limit of normal (ULN) unless
participant is receiving anticoagulant therapy as long as PT or aPTT is within
therapeutic range of intended use of anticoagulants
- Urine or Serum Pregnancy Test = Negative (Not applicable to participants with
bilateral oophorectomy and/or hysterectomy or to those participants who are
postmenopausal).
Exclusion Criteria:
- Severe co-morbidity that would confer excess risk of surgery as determined by the
treating physician.
- Any other major medical illnesses or psychiatric impairments that in the
investigator's opinion will prevent administration or completion of protocol
therapy.
- Is pregnant
- Coagulopathy or platelet dysfunction that increases the risk of intra and
postoperative hemorrhage
- Tumor location requiring DE placement/biopsy in eloquent or critical region of the
brain (e.g. primary motor and sensory cortices, speech and vision centers, thalamus,
basal ganglia, cerebellum, brain stem) as deemed by the neurosurgeon designing the
surgical plan
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Address:
City:
Cleveland
Zip:
44195
Country:
United States
Status:
Recruiting
Contact:
Last name:
Jennifer Yu, MD, PhD
Phone:
866-223-8100
Email:
taussigresearch@ccf.org
Start date:
April 9, 2024
Completion date:
January 1, 2026
Lead sponsor:
Agency:
Case Comprehensive Cancer Center
Agency class:
Other
Collaborator:
Agency:
Burkhardt Brain Tumor and Neuro-Oncology Center
Agency class:
Other
Source:
Case Comprehensive Cancer Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05565118